Modern diagnostics in chronic myeloproliferative diseases (CMPDs).
According to the new WHO classification a group of chronic myeloproliferative diseases (CMPDs) were defined: chronic myeloid leukemia (CML), chronic neutrophilic leukemia (CNL), chronic eosinophilic leukemia and hypereosinophilic syndrome (CEL/HES), polycythemia vera (PV), chronic idiopathic myelofibrosis (with extramedullary hematopoiesis, CIMF), essential thrombocythemia (ET), and so called CMPD/unclassifiable. As clinical features and laboratory findings differ widely between these diseases several diagnostic approaches are mandatory at diagnosis for classification and are needed also for follow up studies, especially for the measurement of minimal residual disease (MRD). We here outline the laboratory set up at diagnosis and during follow up in CMPDs with specific focus on the respective therapeutical consequences. Only by using a comprehensive diagnostic panel including cytomorphology, cytogenetics, and molecular genetic methods establishing the correct diagnosis, optimizing treatment as well as evaluating treatment response is possible in CMPDs today.
Haferlach
T
T
Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, University Hospital Grosshadern, Ludwig-Maximilians-University, Marchioninistreet 15, 81377 Munich, Germany.
Kern
W
W
Schnittger
S
S
Schoch
C
C
D001772:Blood Cell Count; D001853:Bone Marrow / Q000473:pathology; D002908:Chronic Disease; D003937:Diagnosis, Differential; D006801:Humans; D009196:Myeloproliferative Disorders / Q000097:blood / Q000145:classification / Q000175:diagnosis* / Q000473:pathology